Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2025

Pharma News, 2025

US FDA approves Gilead's twice-yearly injection for HIV prevention
US FDA approves Gilead's twice-yearly injection for HIV prevention
June 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences, opens new tab lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and...
Telomir Pharmaceuticals reports positive results for progeria treatment
Telomir Pharmaceuticals reports positive results for progeria treatment
Telomir Pharmaceuticals , Inc. (NASDAQ:TELO) announced positive preclinical data for its lead candidate, Telomir-1, in human progeria cell lines.
Tisento’s MELAS treatment receives fast track status from FDA
Tisento’s MELAS treatment receives fast track status from FDA
Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its investigational oral medicine, zagociguat, for mitochondrial encephalomyopathy
FDA Commissioner’s National Priority Vouchers Will Endanger Americans
FDA Commissioner’s National Priority Vouchers Will Endanger Americans
WASHINGTON, D.C. – The Food and Drug Administration (FDA) has announced a program that will shorten review times assessing safety and efficacy for some new drugs to one to two months.
Hoth Therapeutics reports positive preclinical safety data for HT-KIT
Hoth Therapeutics reports positive preclinical safety data for HT-KIT
NEW YORK - Hoth Therapeutics, Inc., a small-cap biotech company with a market capitalization of $17.17 million,
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’
A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema.
Skye Bioscience to Present Expanded Preclinical
Skye Bioscience to Present Expanded Preclinical
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
European pharma needs scalable models to succeed in US
European pharma needs scalable models to succeed in US
HLTH Europe hosted discussions on the challenges European companies face while entering the US market.
FDA Grants Fast Track Designation to Nuvisertib in Myelofibrosis
FDA Grants Fast Track Designation to Nuvisertib in Myelofibrosis
The U.S. Food and Drug Administration (FDA) granted fast track designation to nuvisertib (TP-3654) for the treatment of patients with intermediate or high-risk myelofibrosis (MF...
Positive preclinical data supports potential of Neurizon’s NUZ-001 in Huntington’s disease
Positive preclinical data supports potential of Neurizon’s NUZ-001 in Huntington’s disease
Neurizon Therapeutics, which is dedicated to advancing treatments for neurodegenerative diseases
ADC Therapeutics shutters UK R&D site
ADC Therapeutics shutters UK R&D site
ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca continues Western big pharma’s growing dependence on Chinese biotechs for drug discovery.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand